文献速递胸部肿瘤

KEYNOTE-021 G队列24个月总生存更新:帕博利珠单抗联合培美曲塞卡铂一线治疗晚期非鳞NSCLC

24-Month Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non-Small Cell Lung Cancer.
PubMed 文献 · J Thorac Oncol · 2018-08-21

KEYNOTE-021 G队列更新分析纳入123例无EGFR/ALK突变的晚期非鳞NSCLC患者,随机接受帕博利珠单抗联合培美曲塞卡铂(PC)或单纯PC一线治疗。中位随访23.9个月时,联合组ORR为56.7% vs 30.2%,PFS HR=0.53,OS HR=0.56,均显著优于单纯PC。

要点

  • 帕博利珠单抗联合PC较单纯PC显著改善ORR(56.7% vs 30.2%)和PFS(HR=0.53)。
  • 中位随访23.9个月时OS HR=0.56(95%CI 0.32-0.95,p=0.0151),支持联合方案。
  • 联合组3-5级治疗相关不良事件发生率为41%,单纯PC组为27%。

核心结论

  • 帕博利珠单抗联合培美曲塞卡铂一线治疗晚期非鳞NSCLC的ORR和PFS获益在更新分析中维持,24个月随访时OS HR为0.56,支持联合方案。

研究设计与样本

  • KEYNOTE-021 G队列随机对照研究,纳入123例既往未治、无EGFR/ALK突变的IIIB/IV期非鳞NSCLC患者,1:1随机接受帕博利珠单抗联合PC或单纯PC治疗。

主要发现

  • 中位随访23.9个月时,联合组ORR为56.7%,单纯PC组为30.2%(估计差异26.4%,95%CI 8.9%-42.4%,p=0.0016)。
  • 联合组PFS显著优于单纯PC组(HR=0.53,95%CI 0.33-0.86,p=0.0049)。
  • OS HR为0.56(95%CI 0.32-0.95,p=0.0151),支持联合组。
  • 单纯PC组有41例患者后续接受了抗PD-1/抗PD-L1治疗。
  • 联合组3-5级治疗相关不良事件发生率为41%,单纯PC组为27%。

临床怎么用

  • 对于无EGFR/ALK突变的晚期非鳞NSCLC患者,一线可考虑帕博利珠单抗联合培美曲塞卡铂方案,需注意联合组3-5级不良事件发生率较高。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Cohort G of KEYNOTE-021 (NCT02039674) evaluated the efficacy and safety of pembrolizumab plus pemetrexed-carboplatin (PC) versus PC alone as first-line therapy for advanced nonsquamous NSCLC. At the primary analysis (median follow-up time 10.6 months), pembrolizumab significantly improved objective response rate (ORR) and progression-free survival (PFS); the hazard ratio (HR) for overall survival (OS) was 0.90 (95% confidence interval [CI]: 0.42‒1.91). Herein, we present an updated analysis. METHODS: A total of 123 patients with previously untreated stage IIIB/IV nonsquamous NSCLC without EGFR and/or ALK receptor tyrosine kinase gene (ALK) aberrations were randomized 1:1 to four cycles of PC with or without pembrolizumab, 200 mg every 3 weeks. Pembrolizumab treatment continued for 2 years; maintenance pemetrexed was permitted in both groups. Eligible patients in the PC-alone group with radiologic progression could cross over to pembrolizumab monotherapy. p Values are nominal (one-sided p < 0.025). RESULTS: As of December 1, 2017, the median follow-up time was 23.9 months. The ORR was 56.7% with pembrolizumab plus PC versus 30.2% with PC alone (estimated difference 26.4% [95% CI: 8.9%‒42.4%, p = 0.0016]). PFS was significantly improved with pembrolizumab plus PC versus PC alone (HR = 0.53, 95% CI: 0.33‒0.86, p = 0.0049). A total of 41 patients in the PC-alone group received subsequent anti‒programmed death 1/anti‒programmed death ligand 1 therapy. The HR for OS was 0.56 (95% CI: 0.32‒0.95, p = 0.0151). Forty-one percent of patients in the pembrolizumab plus PC group and 27% in the PC-alone group had grade 3 to 5 treatment-related adverse events. CONCLUSIONS: The significant improvements in PFS and ORR with pembrolizumab plus PC versus PC alone observed in the primary analysis were maintained, and the HR for OS with a 24-month median follow-up was 0.56, favoring pembrolizumab plus PC.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Borghaei H, Langer CJ, Gadgeel S, et al. 24-Month Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non-Small Cell Lung Cancer. J Thorac Oncol. 2018. PMID: 30138764. doi:10.1016/j.jtho.2018.08.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。